Discrete Choice Experiment in Severe Asthma

Trial description: With increasing treatment options such as Mepolizumab and Omalizumab for severe asthma, there is an increasing need for identification and assessment of subject preferences to improve medication adherence. Therefore the aim of this study is to determine severe asthma subject preference for various treatment attributes like mode of administration, frequency of dosing, willingness to pay, effectiveness, safety using Discrete Choice Experiment (DCE) methodology. DCE is a type of preference study which asks subjects to make a choice between different attributes of importance in the form of a questionnaire. There are 3 stages in design of DCE and after completing all 3 stages, subject preference attributes to be studied will be selected and the DCE subject questionnaire will be developed. In the survey, subjects will be presented with discrete choice between scenarios and will be asked which one they would choose. It is expected that between 30 and 40 subjects with severe persistent asthma will participate in the final online survey from each country (N= ~150-200).